• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

Research Brief on 1-(2-(Methylthio)pyrimidin-4-yl)ethanol (CAS: 910112-38-8) in Chemical Biology and Pharmaceutical Applications

1-(2-(Methylthio)pyrimidin-4-yl)ethanol (CAS: 910112-38-8) is a pyrimidine derivative that has garnered significant attention in recent chemical biology and pharmaceutical research due to its potential as a versatile intermediate in drug discovery. This compound, characterized by its methylthio and hydroxyl functional groups, has been explored for its role in synthesizing bioactive molecules, particularly in kinase inhibitor development and antimicrobial agents. Recent studies highlight its utility in fragment-based drug design (FBDD) and as a building block for targeted therapies.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's application in optimizing allosteric inhibitors of EGFR (epidermal growth factor receptor), where its pyrimidine core facilitated selective binding to T790M/L858R mutant forms. The research team utilized structure-activity relationship (SAR) analysis to modify the methylthio group, achieving a 5-fold increase in potency against resistant cancer cell lines (IC₅₀ = 12 nM). This underscores its value in addressing tyrosine kinase inhibitor (TKI) resistance.

In antimicrobial research, a 2024 ACS Infectious Diseases paper reported 1-(2-(Methylthio)pyrimidin-4-yl)ethanol as a key precursor for novel quorum-sensing inhibitors. The ethanol moiety enabled covalent conjugation to homoserine lactones, disrupting Pseudomonas aeruginosa biofilm formation by 78% at 50 μM concentration. Molecular docking simulations revealed interactions with LasR receptor binding pockets, suggesting a multimodal mechanism of action.

Analytical advancements have also emerged, with a recent Analytical Chemistry publication (2024) detailing a UPLC-MS/MS method for quantifying this compound in biological matrices. The protocol achieved a LOD of 0.1 ng/mL using positive ESI mode and a C18 column (2.1 × 50 mm, 1.7 μm), addressing previous challenges in pharmacokinetic studies of pyrimidine derivatives.

Ongoing clinical-stage research (Phase I/II) by Vertex Pharmaceuticals incorporates 910112-38-8 derivatives in cystic fibrosis transmembrane conductance regulator (CFTR) correctors. Early data show improved chloride transport efficiency (ΔF508del mutation) with reduced hepatotoxicity compared to earlier generations, attributed to the methylthio group's metabolic stability.

Future directions include exploration of deuterated analogs to enhance metabolic half-life and investigations into the compound's potential as a PROTAC (proteolysis targeting chimera) warhead. The 2023-2024 patent landscape shows a 40% increase in filings involving this scaffold, particularly in China and the EU, indicating sustained commercial interest.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)